Add-on treatments with high adoption rates of >50% across all facility types were AHA, chronic endometritis testing and treatment, and AOA, whereas those with low adoption rates of <30% across all facility types were PGT-A, IVM, granulocyte colony-stimulating factor infusion, and IMSI (Table 1). This evidence concerns the gene CSF3 and chronic endometritis.